- Home
- BRY vs ALDX Comparison
BRY vs ALDX Comparison
Compare BRY & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRY | ALDX |
|---|---|---|
| Founded | 1909 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.1M | 293.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | BRY | ALDX |
|---|---|---|
| Price | $3.48 | $4.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $4.00 | ★ $9.50 |
| AVG Volume (30 Days) | 577.5K | ★ 953.0K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $730,290,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $36.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.11 | $1.14 |
| 52 Week High | $5.09 | $7.20 |
Technical Indicators
Market Signals| Indicator | BRY | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 57.85 | 39.04 |
| Support Level | $3.32 | $4.67 |
| Resistance Level | $3.43 | $5.04 |
| Average True Range (ATR) | 0.08 | 0.29 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 88.89 | 3.42 |
Price Performance
Historical ComparisonAbout BRY Berry Corporation (bry)
Berry Corp (bry) is a western United States independent upstream energy company with a focus on the conventional, long-lived oil reserves in the San Joaquin basin of California. Its operating segments includes Exploration and Production (E&P) and Well Servicing and Abandonment. The company generates maximum revenue from the Exploration and Production (E&P) segment.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.